Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Synta Pharmaceuticals Corp.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV NSCLC with measurable disease by RECIST and evidence of progression
Availability of tissue for analysis
ECOG Performance Status 0 or 1
Adequate organ function as defined in the protocol.
Must be at least 18 years old and able and willing to sign a written informed consent document
You may not be if
Poor venous access requiring an indwelling catheter for study drug administration
Women who are pregnant or lactating
Ventricular ejection fraction \< or = to 55% at baseline
Any uncontrolled intercurrent illness
Clareo Health | A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
